Cargando…

Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury

Renal ischemia and reperfusion (I/R) is the major cause of acute kidney injury in hospitalized patients. Mechanisms underlying reperfusion-associated injury include recruitment and activation of leukocytes and release of inflammatory mediators. In this study, we investigated the renal effects of acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barroso, Lívia Corrêa, Silveira, Kátia Daniela, Lima, Cristiano Xavier, Borges, Valdinéria, Bader, Michael, Rachid, Milene, Santos, Robson Augusto Souza, Souza, Danielle Gloria, Simões e Silva, Ana Cristina, Teixeira, Mauro Martins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272821/
https://www.ncbi.nlm.nih.gov/pubmed/22319645
http://dx.doi.org/10.1155/2012/808726
_version_ 1782222844164308992
author Barroso, Lívia Corrêa
Silveira, Kátia Daniela
Lima, Cristiano Xavier
Borges, Valdinéria
Bader, Michael
Rachid, Milene
Santos, Robson Augusto Souza
Souza, Danielle Gloria
Simões e Silva, Ana Cristina
Teixeira, Mauro Martins
author_facet Barroso, Lívia Corrêa
Silveira, Kátia Daniela
Lima, Cristiano Xavier
Borges, Valdinéria
Bader, Michael
Rachid, Milene
Santos, Robson Augusto Souza
Souza, Danielle Gloria
Simões e Silva, Ana Cristina
Teixeira, Mauro Martins
author_sort Barroso, Lívia Corrêa
collection PubMed
description Renal ischemia and reperfusion (I/R) is the major cause of acute kidney injury in hospitalized patients. Mechanisms underlying reperfusion-associated injury include recruitment and activation of leukocytes and release of inflammatory mediators. In this study, we investigated the renal effects of acute administration of AVE0991, an agonist of Mas, the angiotensin-(1–7) receptor, the angiotensin-(1–7) receptor, in a murine model of renal I/R. Male C57BL/6 wild-type or Mas(−/−) mice were subjected to 30 min of bilateral ischemia and 24 h of reperfusion. Administration of AVE0991 promoted renoprotective effects, as seen by improvement of function, decreased tissue injury, prevention of local and remote leucocyte infiltration, and release of the chemokine, CXCL1. I/R injury was similar in WT and Mas(−/−) mice, suggesting that endogenous activation of this receptor does not control renal damage under baseline conditions. In conclusion, pharmacological interventions using Mas receptor agonists may represent a therapeutic opportunity for the treatment of renal I/R injury.
format Online
Article
Text
id pubmed-3272821
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32728212012-02-08 Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury Barroso, Lívia Corrêa Silveira, Kátia Daniela Lima, Cristiano Xavier Borges, Valdinéria Bader, Michael Rachid, Milene Santos, Robson Augusto Souza Souza, Danielle Gloria Simões e Silva, Ana Cristina Teixeira, Mauro Martins Int J Hypertens Research Article Renal ischemia and reperfusion (I/R) is the major cause of acute kidney injury in hospitalized patients. Mechanisms underlying reperfusion-associated injury include recruitment and activation of leukocytes and release of inflammatory mediators. In this study, we investigated the renal effects of acute administration of AVE0991, an agonist of Mas, the angiotensin-(1–7) receptor, the angiotensin-(1–7) receptor, in a murine model of renal I/R. Male C57BL/6 wild-type or Mas(−/−) mice were subjected to 30 min of bilateral ischemia and 24 h of reperfusion. Administration of AVE0991 promoted renoprotective effects, as seen by improvement of function, decreased tissue injury, prevention of local and remote leucocyte infiltration, and release of the chemokine, CXCL1. I/R injury was similar in WT and Mas(−/−) mice, suggesting that endogenous activation of this receptor does not control renal damage under baseline conditions. In conclusion, pharmacological interventions using Mas receptor agonists may represent a therapeutic opportunity for the treatment of renal I/R injury. Hindawi Publishing Corporation 2012 2012-01-29 /pmc/articles/PMC3272821/ /pubmed/22319645 http://dx.doi.org/10.1155/2012/808726 Text en Copyright © 2012 Lívia Corrêa Barroso et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Barroso, Lívia Corrêa
Silveira, Kátia Daniela
Lima, Cristiano Xavier
Borges, Valdinéria
Bader, Michael
Rachid, Milene
Santos, Robson Augusto Souza
Souza, Danielle Gloria
Simões e Silva, Ana Cristina
Teixeira, Mauro Martins
Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
title Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
title_full Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
title_fullStr Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
title_full_unstemmed Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
title_short Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury
title_sort renoprotective effects of ave0991, a nonpeptide mas receptor agonist, in experimental acute renal injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272821/
https://www.ncbi.nlm.nih.gov/pubmed/22319645
http://dx.doi.org/10.1155/2012/808726
work_keys_str_mv AT barrosoliviacorrea renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT silveirakatiadaniela renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT limacristianoxavier renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT borgesvaldineria renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT badermichael renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT rachidmilene renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT santosrobsonaugustosouza renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT souzadaniellegloria renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT simoesesilvaanacristina renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury
AT teixeiramauromartins renoprotectiveeffectsofave0991anonpeptidemasreceptoragonistinexperimentalacuterenalinjury